WaveMan
WaveMan · Company
BIOF · Blue Biofuels, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BIOF Blue Biofuels (BIOF) Insider Trading, Ownership & Congress Trades

Materials · Industrial organic chemicals · CIK 0001549145
Quote by TradingView
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

What the filings say about BIOF

Insiders, 180 days
-$163.6K net sold
1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$240.8K
2 notices

Blue Biofuels insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, BLUE BIOFUELS, INC. insiders sold a net $163.6K of stock across 9 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Kneppers Chris J
Director
SELL
2026-10-22 SECtraded 2026-10-20
125,510
$12.6K
+5.8%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Oct 13, 2026.
  • The trade is 0.6% of the 19,747,167 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Director Kneppers Chris J sold about $12.6K of BIOF on Oct 20, 2026.
Kneppers Chris J
Director
SELL
2026-10-15 SECtraded 2026-10-13
100,000
$10.0K
+1.9%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Sep 8, 2026.
  • The trade is 0.5% of the 19,872,677 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Director Kneppers Chris J sold about $10.0K of BIOF on Oct 13, 2026.
Kneppers Chris J
Director
SELL
2026-09-08 SEC
300,000
$30.0K
+5.8%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Sep 4, 2026.
  • The trade is 1.5% of the 19,972,677 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Director Kneppers Chris J sold about $30.0K of BIOF on Sep 8, 2026.
Kneppers Chris J
Director
SELL
2026-09-08 SECtraded 2026-09-04
200,000
$20.0K
+5.8%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Sep 3, 2026.
  • The trade is 1.0% of the 20,272,677 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Director Kneppers Chris J sold about $20.0K of BIOF on Sep 4, 2026.
Kneppers Chris J
Director
SELL
2026-09-03 SEC
100,000
$10.0K
+2.8%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 2, 2026.
  • The trade is 0.5% of the 20,472,677 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Director Kneppers Chris J sold about $10.0K of BIOF on Sep 3, 2026.
9 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 4 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$163.6K over 180 days
-$163.6K over 90 days
more than 51% of Materials
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-55.3% year over year
below 98% of Materials
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 95% of Materials
What changed in the last 30 days
Oct 22Director Kneppers Chris J sold $22.6K (2 trades, Oct 13 to Oct 20)
Oct 13Director Chris Kneppers filed to sell $90.8K by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch BIOF

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-38.5%12M
-47%-29%-12%+6%2025-102025-122026-022026-042026-062026-082026-10 2026-09-02 · Kneppers Chris J sold $63.0K2026-09-08 · Kneppers Chris J sold $30.0K2026-09-04 · Kneppers Chris J sold $20.0K2026-09-01 · Kneppers Chris J sold $18.0K2026-10-20 · Kneppers Chris J sold $12.6K2026-09-03 · Kneppers Chris J sold $10.0K2026-10-13 · Kneppers Chris J sold $10.0K2026-10-13 · Chris Kneppers filed to sell $90.8K2026-09-03 · Chris Kneppers filed to sell $150.0K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BIOF: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in BIOF

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BIOF planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Chris Kneppers
Filed 2026-10-13
$90.8K
Chris Kneppers
Filed 2026-09-03
$150.0K
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $163.6K sold by insiders over 180 days, $240.8K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
JELDLEGHWMSAVYSXTENTGREXGEVOCMTKOPNKEBNET

BIOF financials

Revenue growth
-55.3%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$1.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.51x
TTM operating cash flow over long-term debt only, 2021-06-30 (60 months older than the period end)
Return on equity
n/a
average equity is zero or negative
Return on assets
-225.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$38.1M
market value at close 2026-10-27 on 2026-08-09 shares, plus long-term debt only, 2021-06-30 (60 months older than the period end), minus cash 2026-06-30
FCF yield
-3.7%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$3.7M-$4.1M-$3.2M-$3.9M
Net income-$2.9M-$1.4M-$3.1M-$4.0M
EPS (diluted)-0.01-0.01-0.01n/a
Operating cash flow-$845.0K-$1.0M-$1.6M-$2.0M
Cash$65.2K$48.8K$41.0K$211.9K
SEC XBRL, fiscal years, as known on 2026-10-28

BIOF Stock Sonar score 4/7 axes

Find similar shapesCompare

BIOF ranks highest on risk and compliance (94th percentile) and insider conviction (25th), and lowest on growth (2nd), among Materials peers.

Financial health
14
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.51x · 14 pct, sector of 103
Growth
2
Inputs
  • Revenue growth, YoY-55.3% · 2 pct, sector of 128
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
25
Inputs
  • Net Form 4 buying (codes P and S), 180d-$164K · 51 pct, sector of 80
  • Insider buyers, 180d0 · 0 pct, sector of 80
Risk and compliance
94
Inputs
  • Short interest, % of float+0.1% · 94 pct, sector of 145
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Profitability, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

BIOF filings, in plain words

Are Blue Biofuels insiders buying or selling BIOF?

In the 180 days to 2026-10-28, Blue Biofuels insiders were net sellers, a net $163.6K across purchases and sales reported on Form 4, by 1 seller.

Are there planned insider sales of BIOF?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $240.8K of stock; the latest, by Chris Kneppers, was filed 2026-10-13.

Read the full summary

In the 180 days to 2026-10-28, Blue Biofuels insiders were net sellers of BIOF, a net $163.6K across purchases and sales reported on Form 4 by 1 seller. None of the 7 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $240.8K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies